Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Savara brings in initial $3.2mm in Series B round; adds $7.4mm

Executive Summary

Pulmonary drug delivery firm Savara Pharmaceuticals has raised $3.2mm so far through its Series B venture round. (An extension to the financing is expected in the near future.) The Keiretsu Forum was joined by current shareholders, for a total of 117 investors. In addition to the new money, Savara raised $3.5mm via a recent bridge financing that converted to Series B shares and $1.9mm from an Emerging Technology Fund equity conversion. Proceeds will be put towards the advancement of AeroVanc through Phase IIa as the first inhaled antibiotic for Staphylococcus aureus in cystic fibrosis patients.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies